0000000000000915

AUTHOR

Tanja Stüber

showing 5 related works from this author

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study.

2017

Abstract Purpose Visceral metastasis of breast cancer (BC) is an alarming development and correlates with poor median overall survival. The purpose of this retrospective study is to examine the risk factors for developing visceral metastasis by considering tumor biology and patient characteristics. Methods Using the BRENDA database, the risk factors such as histological and intrinsic subtypes of BC, age at primary diagnosis, grading, nodal status, tumor size and year of primary diagnosis were examined in univariate and multivariate analysis. Categorical variables were compared by using χ2 tests. Furthermore, multivariate Cox proportional hazards regression models, Kaplan–Meier product-limit…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyMultivariate statisticsMultivariate analysisLung NeoplasmsBreast NeoplasmsKaplan-Meier EstimateLogistic regressionMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerRisk FactorsInternal medicineMedicineHumansGrading (tumors)AgedProportional Hazards ModelsRetrospective StudiesAged 80 and overChi-Square Distributionbusiness.industryCarcinoma Ductal BreastLiver NeoplasmsUnivariateAge FactorsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyLogistic Models030220 oncology & carcinogenesisMultivariate AnalysisSurgeryFemalebusinessBreast (Edinburgh, Scotland)
researchProduct

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

2019

BackgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.MethodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.ResultsIn our study population, patients had a good to excellent prognosis …

0301 basic medicineOncologyDose-dense chemotherapyAdjuvant Chemotherapymedicine.medical_treatmentCancer Treatment0302 clinical medicineBreast TumorsMedicine and Health SciencesEndocrine TumorsMultidisciplinaryPharmaceuticsQREndocrine TherapyMiddle AgedPrognosisSurvival RateOncologyDocetaxelChemotherapy AdjuvantLymphatic Metastasis030220 oncology & carcinogenesisMedicineFemaleLymphAnatomyResearch Articlemedicine.drugClinical Oncologymedicine.medical_specialtyScienceBreast NeoplasmsDisease-Free SurvivalLymphatic SystemCancer Chemotherapy03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancermedicineHumansChemotherapyEndocrine systemSurvival rateAgedRetrospective StudiesChemotherapybusiness.industryBiology and Life SciencesCancers and NeoplasmsRetrospective cohort studymedicine.disease030104 developmental biologyLymph NodesClinical MedicinebusinessPLoS ONE
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

Geburtshilfe und Frauenheilkunde 78(11), 1056-1088 (2018). doi:10.1055/a-0646-4630

medicine.medical_specialtyAdvanced breastPsychological interventionGuideline/LeitlinieSystemic therapymetastasiertes Mammakarzinomprimary breast cancer03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerMaternity and MidwiferyBrustkrebsMedicineprimäres Mammakarzinom030212 general & internal medicineGebFra ScienceIntensive care medicineLeitlinietherapybusiness.industryTumor biologyObstetrics and GynecologyCancerGuidelinemedicine.diseaseMetastatic breast cancerddc:030220 oncology & carcinogenesismetastatic breast cancerbusinessTherapieguideline
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, Germany, 31 Oct 2018 - 3 Nov 2018; Geburtshilfe und Frauenheilkunde 78(10), 927-948 (2018). doi:10.1055/a-0646-4522 special issue: "62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, 31.10 – 03.11.2018 : Frauenheilkunde im Fokus: wissenschaftlich fundiert und der Qualität verpflichtet"

medicine.medical_specialtydiagnosisPsychological interventionComputed tomographyDiseaseGuideline/LeitlinieMammakarzinom03 medical and health sciencesbreast cancerDiagnostik0302 clinical medicineBreast cancerMaternity and Midwiferyfollow-upmedicineMammographyMedical physicsGebFra Science030212 general & internal medicinemedicine.diagnostic_testbusiness.industryscreeningObstetrics and GynecologyCancerGuidelinemedicine.diseaseddc:030220 oncology & carcinogenesisFrüherkennungRichtlinieNachsorgebusinessguidelineSystematic searchGeburtshilfe und Frauenheilkunde
researchProduct